Iksuda Therapeutics
About:
Iksuda Therapeutics is a biotechnology company specializing in the development of next generation biotherapeutics
Website: https://iksuda.com
Twitter/X: iksudat
Top Investors: Mirae Asset Capital, IP Group, Premier Partners, North East Technology Fund, Celltrion
Description:
Iksuda Therapeutics (Iksuda) is the developer of a new generation antibody drug conjugates (ADCs).
Total Funding Amount:
$52M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
Founded Date:
2007-01-01
Contact Email:
info(AT)iksuda.com
Founders:
David Simpson
Number of Employees:
11-50
Last Funding Date:
2021-06-07
IPO Status:
Private
Industries:
© 2025 bioDAO.ai